Clinical trial · Observational
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
NCT04436393CI-TRIAL-00059227GRECO-BcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to observe the routine clinical care of patients who have been diagnosed with breast cancer and have undergone Guardant360 testing.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Guardant360 test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Advanced Breast Cancer
- description
- Patients with diagnosis of advanced breast cancer
- interventionNames
- Diagnostic Test: Guardant360 test
Primary outcomes (3)
- measure
- Overall Survival
- timeFrame
- 18 months post Guardant360 testing
- description
- The Primary Outcome measure is a composite endpoint of: overall survival, progression events, and subjects lost-to-follow-up Overall Survival is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
- measure
- Progression Events
- timeFrame
- 18 months post Guardant360 testing
- description
- The Primary Outcome measure is a composite endpoint of: overall survival, progression events, and subjects lost-to-follow-up Progression events (or progression-free survival) is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adults (18 years of age and older) with a diagnosis of breast cancer 2. Guardant360 test results released to the patient's physician no less than 14 days prior to initial patient contact 3. Patient has previously provided contact information (either email or phone) to Guardant Health 4. Able and willing to complete the electronic informed consent process 5. Must have access to a computer terminal or personal computing device 6. Willingness to consent to the release of medical records Exclusion Criteria: 1\. Unable to understand English
References
Publications (0)
Data not yet available
No reference posted for this study.